PharmaMar, Innovex to build Yondelis(R) sales network across Western Europe
BRACKNELL, United Kingdom, Dec. 3 /PRNewswire/ -- Innovex today
announced a services agreement with PharmaMar, a subsidiary of Zeltia SA,
to recruit, train and deploy a specialized oncology sales team in Western
Europe to promote Yondelis(R), PharmaMar's treatment for soft tissue
sarcoma. PharmaMar, which holds the marketing authorization, will be
responsible for marketing the drug.
Innovex will initially deploy regional unit heads and key account
managers in the United Kingdom, Germany, France, Spain and Italy to promote
Yondelis. The project will be coordinated across these countries by
PharmaMar and an Innovex European project director.
Innovex, a unit of Quintiles Transnational Corp., is the leading global
commercial solutions provider to the pharmaceutical, biotech and medical
device industries.
"Innovex's proven ability to build and launch sales forces across a
multi- country region was a key factor in PharmaMar's selecting us to build
its sales network for Yondelis in Western Europe," said Hywel Evans, Global
President, Innovex. "This is testament to our ability to rapidly recruit,
train and deploy high-performing specialty sales representatives who ensure
our customers achieve their sales objectives."
Yondelis was launched Sept. 19 by PharmaMar in the United Kingdom and
Germany, following its approval by the European Medicines Agency for use in
the treatment of soft tissue sarcoma.
Alfonso Casal, Commercial Director, PharmaMar, said: "This agreement
with Innovex means we can optimize the launch of Yondelis across five
Western European countries as registration and reimbursement allows.
Innovex has demonstrated that they have the ability to recruit high
caliber, experienced oncology representatives that understand the
marketplace and have the technical expertise required in the oncology
market.
"Using Innovex services also gives us both flexibility and scalability
in our future sales force deployment."
The project will be overseen by a joint steering committee of
representatives from PharmaMar and Innovex.
About Innovex
Innovex is the sales and marketing unit of Quintiles Transnational
Corp. Innovex is a leading commercial solutions provider that offers sales
and marketing services designed to accelerate the success of
pharmaceutical, biotechnology and medical device products. Innovex operates
in multiple geographies and ensures that high quality sales solutions can
be provided where the customer needs them -- locally, regionally and across
multiple countries. For more information, visit http://www.innovex.com.
About Quintiles
Quintiles Transnational Corp. is powering the next generation of
healthcare by providing a broad range of professional services in drug
development, financial partnering and commercialization for the
biotechnology and healthcare industries. With 20,000 employees and offices
in more than 50 countries, it is focused on providing customer-centric
solutions that are the gold standard of the industry. For more information,
please visit the company's Web site at http://www.qtrn.com.
About PharmaMar
PharmaMar is the world leader biopharmaceutical company of the Zeltia
Group, committed to advancing the treatment of cancer through the discovery
and development of new marine-derived medicines. PharmaMar has five novel
compounds: Yondelis(r) has received Authorization for Commercialization
from the European Commission for advanced soft tissue sarcoma, after
failure of anthracyclines and ifosfamide, or for patients who are unsuited
to receive these agents. Yondelis(r) is also in phase III for ovarian
cancer and phase II for prostate, breast and pediatric cancers. Aplidin(r),
Kahalalide F, Zalypsis(r) and PM02734 are in clinical trials. PharmaMar
also has a rich pipeline of preclinical candidates, and a strong R&D
program.
SOURCE Innovex
 back to top
Related links:
http://www.innovex.com
http://www.qtrn.com
CONTACT:
Charlotte Taylor, Executive Director
Communications, Innovex, +44 1344 708386,
charlotte.taylor@innovex.com
|
